UK body shaping cost-effective health care and guidance
UK pharmacies are now able to offer orforglipron (Foundayo), the second GLP-1 pill for weight loss, following MHRA approval. The pill, manufactured by Eli Lilly, is available initially by private prescription while NICE assesses a potential NHS rollout in England. It targets BMI thresholds (30+, or 27-30 with weight-related conditions) and is taken daily with no food or water restrictions.
Recent reporting shows targeted drugs, immunotherapies and refined radiochemotherapy are prolonging life for cancer patients. Trials indicate higher survival in younger groups and expanding use of genomic profiling. New therapies are pairing with existing treatments to push back relapse and increase quality of life, though access and long-term outcomes vary.
Nice has issued a draft guideline for PMOS that mandates annual checks, earlier diagnosis, and monitoring of long-term risks. It renames the condition from PCOS to PMOS to reflect broader health impacts. It also rules out laser hair removal as a cost-ineffective treatment, instead urging contraception-based management and IVF options where appropriate.
Foundayo, the oral GLP-1 weight-loss pill by Eli Lilly, has been authorised by the MHRA for weight management and type 2 diabetes. It will be available privately; NHS adoption depends on NICE evaluation. Several UK outlets report on uptake, pricing, side effects and competing pills, including Wegovy and Wegovy HD.
Cambridge and ICR researchers show NICE criteria miss up to 95% of women under 50 who will develop breast cancer within 10 years. A new model called Boadicea identifies eight times as many high-risk women, prompting calls for review and investment to implement multifactorial risk assessment across the NHS.
Athletes and patients have urged Downing Street to appoint a national brain cancer lead and boost research funding. The Rare Cancers Bill is seen as a step forward but not enough, with calls for faster action in light of Commonwealth Games coverage and ongoing treatment campaigns.